SCHEMBL5418328

SCHEMBL5418328

CCOC(=O)c1cc(C2CC2)c2c(C)c(-c3ccccc3C)ccn2c1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 11/20 0.47
ALDH1A1 P00352 9/20 0.47
HPGD P15428 6/20 0.47
GAA P10253 5/20 0.47
GLA P06280 4/20 0.47
NPSR1 Q6W5P4 2/20 0.40
RXFP1 Q9HBX9 1/20 0.40
MAPT P10636 6/20 0.38
MAPK1 P28482 2/20 0.38
ATM Q13315 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
HSD17B10 Q99714 4/20 0.37
KMT2A Q03164 4/20 0.37
POLB P06746 1/20 0.37
STAT6 P42226 1/20 0.37
HIF1A Q16665 1/20 0.37
TSHR P16473 2/20 0.36
MEN1 O00255 2/20 0.36
USP2 O75604 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5423221 0.89 KDM4E (0.43) KDM4EALDH1A1HPGDGAAGLA
SCHEMBL1290252 0.88 KDM4E (0.41) KDM4EALDH1A1HPGDGAAGLA
SCHEMBL5421645 0.86 DHODH (0.37) KDM4EALDH1A1GAA
SCHEMBL1290222 0.85 KDM4E (0.43) KDM4EALDH1A1HPGDGAAGLA
SCHEMBL1290164 0.83 KDM4E (0.41) KDM4EALDH1A1HPGDGAAGLA
SCHEMBL5418075 0.83 KDM4E (0.41) KDM4EALDH1A1HPGDGAAGLA
SCHEMBL1290318 0.83 KDM4E (0.41) KDM4EALDH1A1HPGDGAAGLA
SCHEMBL1290014 0.83 KDM4E (0.43) KDM4EALDH1A1HPGDGAAGLA
SCHEMBL1290075 0.83 KDM4E (0.38) KDM4EALDH1A1HPGDGAAGLA
SCHEMBL4966503 0.83 ALDH1A1 (0.44) KDM4EALDH1A1HPGDGAAGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7223773-B2 4-oxoquinolizine antibacterial agent having 2-pyridone skeleton as partial structure SALO PHARMACEUTICAL CO., LTD. (JP) 2007-05-29 US disclosed
US-20040229903-A1 4-Oxoquinolizine antibacterial agent having 2-pyridone skeleton as partial structure SATO PHARMACEUTICAL CO., LTD. (JP) 2004-11-18 US disclosed
EP-1437354-A1 4-OXOQUINOLIZINE ANTIMICROBIALS HAVING 2-PYRIDONE SKELETON AS PARTIAL STRUCTURE Sato Pharmaceutical Co. Ltd. (JP) 2004-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229903-A1 4-Oxoquinolizine antibacterial agent having 2-pyridone skeleton as partial structure SDHA, IL4I1, BLVRB KDM4E 161/4885ALDH1A1 789/4885HPGD 270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.